Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by Landroon Mar 04, 2010 4:29pm
441 Views
Post# 16844738

RE: what to do with the $

RE: what to do with the $No, I don't believe the SP would rise...quite the contrary actually.

It is typical to see the sp of  the initiator of a takeover take a nosedive. Furthermore, in the case of NRI, there is (unfortunately) a perpetual negative market perception that will only be beaten when hard dollar revenues are pouring in. Since the FDA approval, the markets have CLEARLY demonstrated that potential revenues are worth squat for NRI. Adding a 'late stage drug' would only increase market uncertainty and push any potential sp upside way, way further in the future.

Let's all remember that it took years and years to get Pennsaid approved by the FDA  after the Canadian and some European authorities approved it. Pennsaid would certainly have qualified as a 'late stage drug' in 2002 yet it took another 7 years to get it approved for the only market that really counts.

As I have been saying for the last tree months, I want our Co-CEO's to use our money to initiate a significant share buy-back program so that they would undo some of the dilution they forced upon small shareholders.

I also want them to do a much better job in leveraging the FDA approval from a PR standpoint. All of their defenders on this board seem to forget that world class compensation should provide us with world class managers. I have not seen world class managers since November 5th. Considering the current share price, neither did the markets...



Bullboard Posts